MedTrace Logo

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

NCT01839968 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2014-08-19

No results posted yet for this study

Summary

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Conditions

  • Acquired Platelet Disorder

Interventions

OTHER

Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01839968 on ClinicalTrials.gov